10 results about "Taxane Compound" patented technology

This invention discloses the preparation method and application of lipid prodrugs and self-microemulsion formulations of taxane compounds, belonging to the field of pharmaceutical technology. This invention discloses two lipid prodrugs substituted with long-chain fatty acids at positions 1,3, bridged by disulfide bonds, as shown in the following formula. The aim is to improve the oral absorption efficiency of ralotathol and SB-T-1214, promote their specific release at the target site, and achieve synergistic effects and reduced toxicity. The self-microemulsion drug delivery system is suitable for lipid-soluble drugs and has advantages such as simple preparation process, high drug loading, and easy process scale-up. The prepared self-microemulsion formulation consists of ralotathol or SB-T-1214 lipid prodrugs and excipients. The excipients include an oil phase and an emulsifier. By mass percentage, the oil phase accounts for 40-75% of the self-microemulsion formulation, the emulsifier accounts for 25-60%, and the ralotathol or SB-T-1214 lipid prodrug accounts for 1-10% of the total mass of the excipients.

Provided are a terpene compound epoxidase and the use thereof. Provided is a terpene compound epoxidase. The terpene compound epoxidase has an amino acid sequence as shown in any one of SEQ ID NO. 1-SEQ ID NO. 8, shows epoxidase enzymatic activity, and is capable of performing epoxidation catalysis on taxadiene or a hydroxylation product of taxadiene or an acetylation product of taxadiene so as to generate a corresponding epoxidized terpene compound. The terpene compound epoxidase can be used to improve the taxane compound biocatalysis pathway so as to improve the biocatalysis efficiency of taxane compounds (for example, paclitaxel).

The present disclosure provides a novel taxane-based compound having a structure represented by Formula (I), a preparation method thereof, and a use thereof in preparation of anti-tumor drugs.

The present disclosure relates to the field of biomedicine, and particularly relates to combined use of a YAP / TAZ-TEAD interaction inhibitor and a taxane compound. Specifically, the present disclosure provides use of the YAP / TAZ-TEAD interaction inhibitor in combination with a taxane drug in the preparation of a medicament for treating and / or preventing cancer. The combination of the YAP / TAZ-TEAD interaction inhibitor with the taxane drug exhibits more significant efficacy in treating cancer than the treatment with paclitaxel alone.

Disclosed herein are methods, including methods for determining a response to treatment comprising ADT and a taxane compound, for example docetaxel, that a subject with metastatic prostate cancer is expected to have based on at least the expression level a plurality of targets in the sample from the subject. In some embodiments, the methods include administering or having administered to the subject with metastatic prostate cancer in a treatment selected from: a treatment comprising ADT and a taxane compound, for example docetaxel; or a treatment comprising ADT and not comprising a taxane compound, for example docetaxel, wherein the treatment is selected based on the expected response to treatment comprising ADT and the taxane compound, for example docetaxel. Also disclosed are kits and reagents used for performing the methods.

The application discloses a kind of compositions for enhancing chimeric antigen receptor T cell function and preparation method and application thereof, belong to cell immunotherapy technical field.The composition described in the application comprises subcytotoxic concentration of taxane compound and pharmaceutically acceptable carrier, wherein the concentration of taxane compound is preferably 1-50 nM.Embodiment results show that the composition is used for pretreatment CAR-T cell, induces it to enter a specific state of metabolic active and effect function enhancement.Processed CAR-T cell shows that the proportion of memory phenotype increases, the expression of exhaustion marker decreases, the expression of cytotoxicity effector molecule is up-regulated, and is accompanied by the change of specific extracellular vesicle secretion activity.The application also provides a preparation method of function-enhanced CAR-T cell;The scheme provides a non-genetic strategy, which can improve the persistence and antitumor effect of CAR-T cell in solid tumor treatment, and has important clinical application value.

This invention relates to a lalotasyl-derived taxane compound, specifically a compound of general formula (I) or a pharmaceutically acceptable salt thereof. Wherein R 1 Selected from hydrogen, C 1‑6 Alkyl, cycloalkyl, aryl, or benzyl groups. This invention also provides methods for preparing the compounds and their use in the preparation of medicaments for the prevention and / or treatment of tumors. In vitro antitumor activity tests show that these compounds have significant inhibitory activity against various human cancer cell lines, including non-small cell lung cancer cell line A549, breast cancer cell line MCF-7, triple-negative breast cancer cell line MDA-MB-231, glioblastoma cell line U251, paclitaxel-resistant non-small cell lung cancer cell line A549Tax, and doxorubicin-resistant breast cancer cell line MCF-7 / ADR. Some of these compounds showed 136-462 times greater activity against A549 cells than lalostatin. The compounds of this invention possess excellent antitumor activity and are expected to be used in the preparation of medicaments for the treatment of tumors such as lung cancer, breast cancer, or glioma.

The present disclosure provides a novel taxane-based compound having a structure represented by Formula (I), a preparation method thereof, and a use thereof in preparation of anti-tumor drugs.

The present invention relates to the field of plant diterpenoid synthesis, and in particular host cells, methods and uses therefor. More specifically, the invention relates to production of taxol and / or other taxanes having a side chain comprising an N- benzoylated or an N-acetylated β-phenylalanine moiety, as well as enzymes and host cells useful for such production.

The invention discloses a crocetin bridged taxane dimer prodrug as well as a preparation method and application thereof, and belongs to the technical field of biological medicines, the dimer prodrug is formed by bridging one molecule of crocetin with two molecules of taxane compounds through an ester bond; the taxane compound has a C2 '-site hydroxyl group, and the hydroxyl group is covalently connected with a carboxyl group of crocetin through an ester bond. Specifically, crocetin serves as a molecular bridge, dicarboxyl of crocetin and C2'hydroxyl of two-molecule paclitaxel are subjected to esterification coupling, and the crocetin-bridged paclitaxel dimer prodrug is constructed, the lipophilicity of paclitaxel is enhanced through the prodrug, and meanwhile toxicity to normal tissue is reduced through the synergistic effect of crocetin.